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 CURRENTOPINION Towards an integrated morphological and molecular
WHO diagnosis of central nervous system tumors:
a paradigm shift
Elisabeth J. Rushinga and Pieter Wesselingb,c
Purpose of review
It is now fully clear that information on the molecular underpinnings of tumors of the central nervous system
(CNS) can be used for a more robust characterization of at least selected neoplasms. During a meeting
organized in Haarlem, The Netherlands, in May 2014, about 30 neuropathologists discussed how exactly
molecular information could be incorporated in the routine classification of CNS tumors.
Recent findings
This meeting laid the groundwork for an update of the WHO CNS tumor classification that integrates
histopathological and molecular findings. Furthermore, a layered diagnostic approach was proposed that
not only allows for integration of relevant molecular information in the pathological diagnosis, but also
retains the option for rendering a diagnosis based on histopathological analysis alone. An integrated
morphological and molecular definition of CNS tumors brings new challenges as well. For example,
criteria for grading within molecularly defined categories of diffuse gliomas will require modification, and
some tests used in clinical practice for the detection of molecular features, may provide false positive or
false negative results.
Summary
The evolving paradigm shift represents a major leap forward in the diagnosis of CNS tumors that will
contribute substantially to optimizing interobserver reproducibility and clinico-pathological predictions.
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INTRODUCTION
The last two decades havewitnessed seminal advan-
ces in our understanding of the molecular biology
of tumors of the central nervous system (CNS).High
throughput genetic profiling has facilitated the
unbiased identification of genes differentially
expressed in these tumors, which in turn has
yielded new diagnostic biomarkers and potential
therapeutic targets. Perhaps more surprising is the
discovery that not only DNA-based alterations, but
also epigenetic processes independent of the DNA
sequence (histone modification, CpG island meth-
ylation, and dysregulation of DNA binding
proteins) are co-conspirators in CNS tumor onco-
genesis. The obvious question arises as to how these
unprecedented advances should be incorporated in
the routine classification of brain tumors. Although
for many entities the traditional morphologic
criteria of the WHO Classification of Tumors of
the Central Nervous System [1] have stood the test
of time, the genetic and epigenetic landscape of
certain entities have shown a better correlation
with prognosis. As a practical example, de-novo
(primary) and secondary glioblastomas are histopa-
thologically indistinguishable. However, at the
genetic and epigenetic levels they show significant
differences that potentially impact patientmanage-
ment [2,3]. At present, the classification of CNS
tumors based on histopathological criteria alone
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is undergoing a major revision in an attempt to
integrate these rapidly emerging discoveries into
daily practice. In May 2014, the International
Society of Neuropathology (ISN)-Haarlem WHO’s
Next conference was convened to develop general
practice guidelines for the neuropathology com-
munity [4] that would reflect the contribution of
these advances and help lay the groundwork for the
next WHO classification of CNS tumors, which is
projected to be published in the first half of 2016.
The aim of the present article is to draw attention to
the ISN-Haarlem guidelines, to highlight several
publications that illustrate key advances towards
a more rational classification scheme for CNS
tumors, and to indicate some aspects that need
more attention, now that molecular characteristics
are increasingly used for classification.
INTERNATIONAL SOCIETY OF
NEUROPATHOLOGY-HAARLEM WHO’S
NEXT GUIDELINES
In preparation for the Haarlem meeting, the partici-
pants, most of whom were neuropathologists with
ample expertise in molecular diagnostics of tumors
of the CNS, were asked to consider if and how
molecular data should be used in the classification
of brain tumors. Additional subquestions were
posed that related to whether molecular analyses
should be mandatory for entities with a defining
molecular aberration, and if so, how the results
should be reported. Various scenarios were discussed
including how to report the histopathological find-
ings when molecular analyses are ongoing and the
preferred strategy for diagnostic sites where molecu-
lar diagnostic tools are unavailable. The consensus
was that, when available, molecular genetic or epi-
genetic signatures should be routinely used to define
previously ambiguous categories. Furthermore, it
was concluded that CNS tumors in children often
differ clinically and biologically from their histo-
logically similar adult counterparts and therefore
merit separate classification criteria. With respect
to the reporting of imaging and clinical findings, the
consensus was not to formerly integrate these
aspects into the pathologic diagnosis. Another
important conclusion from the Haarlem meeting
was that improved classification of CNS tumors will
depend on a successful partnership between biol-
ogists, clinicians, and neuropathologists.
Obviously, the application of characteristic mol-
ecular markers would prove especially useful to
enhance diagnostic acumen when histopathological
criteria are not sufficiently precise for recognition of
clinically relevant subgroups and/or when tissue
specimens are small or lack all the cardinal morpho-
logic features of a specific entity. Atypical teratoid/
rhabdoid tumor (AT/RT), aWHOgrade IV embryonal
tumor with rhabdoid features under themicroscope,
represents a test case. The consensus now is that
‘canonical’ AT/RTs carry a SMARCB1 or (rarely)
SMARCA4 mutation, and that for the diagnosis of
AT/RT one of these mutations should be demon-
strated using molecular diagnostics. Alternatively,
sound evidence for the presence of these mutations
can be provided by demonstrating loss of, respect-
ively, nuclear INI1 or BRG1 protein expression using
immunohistochemistry. The final diagnosis would
thus rest on the stepwise integration of morphologic
with immunophenotypic and/or molecular data. In
daily clinical practice an initial, descriptive histopa-
thologic classification (‘embryonal tumor with rhab-
doid features’) could be rendered, pending the
integration of molecular analyses, which would be
incorporated into a second report and lead to a final
diagnosis of AT/RT (in case the molecular infor-
mation supports this diagnosis) or of embryonal
tumor with rhabdoid features (when no evidence
of SMARCB1 or SMARCA4mutation is found). Mean-
while, acknowledging that inmolecularly ‘bona fide’
AT/RTs rhabdoid features may be lacking [5], using a
combined morphological and molecular diagnostic
approach, a high-grade malignant embryonal CNS
tumor lacking rhabdoid featuresbutwithout staining
of tumor cell nuclei for INI1 or BRG1 as well, can still
be diagnosed as AT/RT.
OLIGODENDROGLIOMA, ADVENT OF THE
MOLECULAR AGE
For the group of diffuse gliomas (diffuse astrocytic
tumors including glioblastomas, and oligodendro-
glial tumors), molecular diagnostics are very helpful
for improved classification as well. Oligodendroglial
tumors represent a forerunner for the role of molecu-
lar diagnosis in CNS tumor classification. The 2007
WHO classification recognizes two basic categories:
pure oligodendroglioma and mixed oligoastrocy-
toma, which can be either ‘low-grade’ (grade II),
KEY POINTS
 New classification schemes will be based on genetic
and epigenetic signatures of brain tumors.
 A layered morphologic-molecular diagnostic approach
will likely become the new diagnostic ‘gold standard’.
 Pediatric brain tumors are biologically different from
their adult counterparts and require different
diagnostic criteria.
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‘anaplastic’ (grade III) or, in the case of a mixed
phenotype with necrosis, ‘glioblastoma with oligo-
dendroglial component’ (grade IV) [1]. Although clas-
sic oligodendroglioma seldom poses a diagnostic
dilemma, the lack of stringent criteria for diffuse
gliomas with ambiguous features continues to erode
the prognostic importance of assigning aWHOgrade.
Many neuropathologists have defaulted to themixed
oligoastrocytoma category when confronted with
such cases. Not surprisingly, previous studies have
shown poor interobserver reliability in capturing
the morphologic distinction between these entities
[6–8].
The recognition thatdiffuse gliomaswitha classic
oligodendroglial phenotype frequently show com-
bined loss of the short arm of chromosome 1 and
of the long arm of chromosome 19q (1p19q codele-
tion) represented the first milestone in identifying a
potential biomarker [9]. Subsequently, the obser-
vation that the molecular signature was linked to a
better prognosis [8,10] heralded a new era in brain
tumor classification and fueled the debate as to
whether oligodendroglioma should be defined by a
molecular signature. A very recent, comprehensive
review of the subject not only describes the differen-
tial diagnosis with occasional morphologic mimics
such as pilocytic astrocytoma, glioneuronal tumors,
and clear-cell ependymoma, but also emphasizes that
with molecular diagnostics, the vast majority of dif-
fuse gliomas in adults can be successfully separated
into clinically relevant oligodendroglial or astrocytic
tumors [11]. Consequently, the diagnosis of mixed
oligoastrocytomacanbeexpected to largelydisappear
when adequate molecular analysis can be performed
[12]. Standardmarkers that are recommended for use
in a diagnostic algorithm include immunohisto-
chemistry for the isocitrate dehydrogenase 1 (IDH1)
R132H mutant protein and for ATRX (alpha thalas-
semia mental retardation syndrome X linked), a
critical chromatin modifier, which often shows loss
of nuclear expression in IDH mutant astrocytic
tumors and but preservation in oligodendrogliomas.
For tumors immunonegative for IDH1R132Hmutant
protein, further molecular-based analyses are indi-
cated to exclude less common other IDH1 or IDH2
mutations [13]. The consensus at the ISN-Haarlem
meeting was that complete 1p19q codeletion indeed
represents a valid surrogate marker for oligodendro-
glioma that substantially aids in establishment of
prognosis and treatment selection. The term ‘not
otherwise specified’ (NOS) designation could be
added to the diagnosis in cases histologically diag-
nosed as oligodendroglioma without such molecular
diagnostic support [4].
As detailed in the review article on oligodendro-
glioma [11], each method for assessment of the
1p19q codeletion status has its advantages and dis-
advantages. A pitfall for the frequently used fluor-
escent in situ hybridization (FISH) technique is that
partial deletions of these chromosome arms are
difficult to discriminate from complete 1p19q code-
letion.Meanwhile, it is now clear that only the latter
form of codeletion has a prognostically favorable
impact. Another promising biomarker for improved
classification of diffuse gliomas is the TERT pro-
moter mutation. Interestingly, this mutation is
mutually exclusive with ATRX mutations and is
paradoxically seen in oligodendrogliomas and IDH
wild-type high-grade gliomas [14].
GLIOBLASTOMA, A CHINK IN THE WALL
Until recently, the histopathological diagnosis pro-
vided the foundation for diagnosis, and importantly,
a critical basis for therapy selection and outcome
prediction for patients with a diffuse glioma. Current
histopathological criteria for the diagnosis of glio-
blastoma, however, fail to adequately mirror the
enormous biologic complexity of the entity. For
the most part, morphologic subtypes such as giant
cell glioblastoma, small cell glioblastoma, and glio-
sarcoma have not proven relevant for therapeutic or
prognostic stratification. At themolecular level, with
the exception of less frequent O6-methylguanine
methyltransferase (MGMT) promoter methylation
and epithelial growth factor receptor (EGFR)
mutations, gliosarcoma is identical to glioblastoma
without such sarcomatoid features. Similarly, almost
all giant cell glioblastomas harbor TP53 mutations,
yet are clinically indistinguishable from convention-
al glioblastoma [15,16]. The concept of primary ver-
sus secondary glioblastoma was traditionally based
on the recognition that glioblastoma can either arise
de novo or through progression from a lower-grade
diffuse astrocytoma. Indeed, such a dichotomy has
nowbeen validated by evidence of distinctmolecular
profiles, with secondary glioblastomas generally
being IDH mutant and primary glioblastomas, IDH
wild type. In addition, secondaryglioblastomasoften
carry mutations in the ATRX and TP53 genes,
whereas primary glioblastomas typically show EGFR
amplification, gain of chromosome 7, and loss of
chromosome 10 [3,16]. Although the diagnosis of
glioblastoma with an oligodendroglial component
(GBM-O) was mentioned in the 2007 WHO classifi-
cation, the preponderance of molecular evidence
now dismisses GBM-O as a particular subtype of
glioblastoma. After assessment of 1p19q status and
ofmolecularmakers suchasEGFRamplification, gain
of chromosome 7, and loss of chromosome 10, most
cases can readily be assigned to either the anaplastic
oligodendroglioma or glioblastoma category [11,17].
Neoplasms
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Aldape et al. [16] systematically reviewed the
contributionof twodecadesofglioblastomaresearch,
covering a range of topics that include genomic
analysis,molecularpathogenesis, and transcriptional
subtypes. Based on the observation that histologic
grade III (anaplastic astrocytoma) and grade IV (glio-
blastoma) astrocytic tumors share key molecular
chromosomal changes, the authors pose the provo-
cative question of whether IDH-mutation status
should replace traditional histopathological criteria
[17]. Indeed, recent reports suggest that criteria for
grading of diffuse gliomas need to be revised. For
instance, the prognostic impact of assigning grade
II versus grade III to an IDHmutant astrocytic tumor
may not be that different any more [18,19]. Further-
more, most lower grade (i.e.WHOgrade II or III) IDH
wild-type diffuse astrocytomas appear to be biologi-
cally aggressive and behave as glioblastoma, even in
the absence of microvascular proliferation and/or
necrosis [16,20].
At the epigenetic level, promoter methylation of
the MGMT gene, which can be assessed by several
methodologies including methylation-specific PCR
or pyrosequencing, is nowpart of the standard evalu-
ationof high-grade astrocytomas.Methylation of the
MGMT promoter is associated with a better response
of glioblastoma to alkylating chemotherapy using
temozolomide. Interestingly, most IDH mutated
diffuse gliomas show MGMT promoter methylation
in the context of a hypermethylated DNA status
(‘glioma CpG island methylated phenotype’, G-
CIMP). The G-CIMP status results from the ‘oncome-
tabolite’ 2-hydroxyglutarate (2-HG) that is produced
in excess because of the IDH mutation [15,21].
AGE MATTERS
Comprehensive genetic and epigenetic studies have
yielded compelling evidence that pediatric brain
tumors are fundamentally different from morpho-
logically similar tumors inadults. At the topof the list
of clinically actionable discoveries in pediatric CNS
tumors is themolecular subclassification ofmedullo-
blastoma, which include the SHH and WNT
pathways [22,23]. Pilocytic astrocytoma, a far more
commonchildhoodbrain tumor, is nowconsidered a
one-pathway disease involving the MAPK pathway.
Frequent underlyingmolecular aberrations include a
tandem duplication on chromosome 7 resulting in
theKIAA1549–BRAF fusion protein and BRAFV600E
mutation [24]. Other notable discoveries in pediatric
gliomas include the lysine to methionine (K27M)
substitution in histones H3.1 and H3.3 in over 80%
of diffuse midline gliomas including diffuse intrinsic
pontine gliomas. In contrast to adults, IDH1 or IDH2
mutations and/or 1p19q codeletion are virtually
absent in pediatric diffuse gliomas [25–27]. The rare
tumors previously designated embryonal tumorwith
abundant neuropil and true rosettes, ependymoblas-
toma,ormedulloepitheliomawere recently shownto
share molecular similarity and to in fact comprise a
single clinicopathological entity. This entity is now
tentatively grouped under the term ‘embryonal
tumor with multilayered rosettes’, which can now
be reliably diagnosed by combined LIN28A immu-
nohistochemistry and FISH analysis of the 19q13.42
locus [28,29]. Advances have even been made in the
molecular classification and prognostic stratification
of ependymomas, which are long overdue, given the
inconsistent results that have plagued histological
grading [30].
CONCLUSION
The ISN-Haarlem WHO’s Next meeting has laid the
groundwork for an evolving paradigm of CNS tumor
classification that integrates histopathological and
molecular results in a layered fashion. This layered
diagnostic approach not only allows for the integ-
ration of relevant molecular information in the
pathological diagnosis but also retains the option
of a histopathological diagnosis for centers/countries
where molecular diagnostics is not available. Mean-
while, it is fully clear that the expanding catalogue of
molecular markers has at the same time contributed
to the elucidation of the pathogenesis of CNS neo-
plasms and to improved diagnostic stratification. It
can be expected that the rapid pace of discoveries in
(CNS) tumor biology and genetics that have marked
the last decade will continue to refine diagnostic
strategies. Hopefully, translation of these discoveries
will facilitate the development and selection ofmore
effective therapies for thepatients suffering fromCNS
tumors as well.
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